J. Jamal Trevillyan icaac 2012 finalprogram web4a

58 SCIENTIFIC SESSIONS September 9-12 | T-348 Diseases Due to Scedosporium in the First Year Following Transplant Tx Often Stem from Colonization or Surgical Seed- ing, and are Associated with High Mortality

L. Johnson, R. K. Shields, C. Clancy; Univ. of Pittsburgh, Pittsburgh, PA. T-349

The Epidemiology and Outcomes of Candidemia in Hemato- poietic Cell Transplantation

L. Gold J. Kriengkauykiat, B. Tegtmeier, S. Dadwal, J. Ito; City of Hope, Duarte, CA.

T-350 Posaconazole PCZ Serum Levels for Treatment Tx and Prophylaxis Px in Immunocompromised Patients

M. Rhee

1 , J. Ito 2 , S. Dadwal 2 , B. Tegtmeier 2 , J. Kriengkauykiat 2 ; 1 Western Univ. of Hlth. Sci., Pomona, CA, 2 City of Hope, Duarte, CA. T-351 Human Herpesvirus Type-6 HHV6 Reactivation in Patients pts with Unrelated Donor Hematopoietic Cell Transplantation HCT: Comparison of Outcomes amongst Treated and Un- treated

T. Bui, J. Kriengkauykiat, J. Ito, B. Tegtmeier, S. Dadwal; City of Hope, Duarte, CA.

T-352 Chronic High EBV Load Carriage Has Low Predictive Value to Detect Post-Transplant Lymphoproliferative Disorder PTLD in Solid-Organ Transplant Recipients

C. Gardiol, P. Meylan, M. Pascual, O. Manuel; Univ. Hosp. Ctr. of Laus- anne, Lausanne, Switzerland.

T-353 The Molecular Epidemiology of a Respiratory Syncytial Virus Outbreak Among Oncology and Hematopoietic Stem Cell Trans- plant HSCT Patients H. Y. Chu, S. Podczervinski, J. Kuypers, A. P. Campbell, M. Boeckh, J. Englund, C. Casper; Univ. of Washington, Seattle, WA. T-354 BK Virus BKV Infection after Reduced Intensity Double Umbilical Cord Blood Stem-Cell Transplantation dUCBT

G. Satyanarayana

1 , S. Hammond 2 , T. A. Broge Jr. 1 , R. Viscidi 3 , I. Politikos 1 , I. J. Koralnik 1 , C. Cutler 4 , K. Ballen 5 , V. A. Boussiotis 1 , F. Marty 2 , S. Tan 1 ; 1 Beth Israel Deaconess Med. Ctr., Boston, MA, 2 Brigham and Women’s Hosp., Boston, MA, 3 Johns Hopkins Univ., Baltimore, 4 Dana Farber Cancer Inst., Boston, MA, 5 Massachusetts Gen. Hosp., Boston, MA. T-355 CMV Antigenemia and Quantitative Viral Load Assessments in Hematopoietic Stem Cell Transplant Recipients L. Cardeñoso 1 , B. Pinsky 2 , I. Lautenschlager 3 , S. Aslam 4 , B. Cobb 4 , R. Vilchez 4 , H. Hirsch 5 ; 1 Hosp. Univ.ersitario de la Princesa, Madrid, Spain, 2 Stanford Univ. Sch. of Med., Stanford, CA, 3 Helsinki Univ. Hosp., Univ. of Helsinki, Helsinki, Finland, 4 Roche Molecular SysteInc., Pleasanton, CA, 5 Univ. of Basel, Basel, Switzerland. T-356 Letermovir AIC246 for the Prevention of CMV Infections Meets Primary Endpoint in Phase 2b Trial in Human Blood Pre- cursor Cell Transplant HBPCT Recipients

R. F. Chemaly

1 , G. Ehninger 2 , R. Champlin 1 , for the AIC246 Study Team, M. Richard 3 , H. Zimmermann 3 , P. Lischka 3 , S. Stoelben 3 , D. McCormick 3 , H. Ruebsamen-Schaeff 3 ; 1 UT MD Anderson Cancer Ctr., Houston, TX, 2 Univ. Dresden, Dresden, Germany, 3 AiCuris GmbH Co. KG, Wuppertal, Germany. T-357 Treatment of RSV in Adult Transplant Recipients with Palivi- zumab 7.5mgkg, Inhaled Ribavirin, IVIG, and Steroids J. Gillman, P. Mohazabnia, R. Portinari, Pharm.D, W. Tharpe, B. De Marco, F. Lee, B. M. Le; Univ. of Texas Southwestern Med. Ctr., Dallas, TX. T-358 Preemptive Therapy PrT for Cytomegalovirus CMV Posthematopoietic Cell Transplantation HCT is Associated with Significant Morbidity and Resource Utilization

H. Mommeja-Marin, S. Godkin, T. Brundage, W. Painter, D. Margolskee; Chimerix, Durham, NC.

T-359 Impact of Adjuvanted Pandemic H1N1 2009 Influenza Vac- cine on Acute Rejection Rate and Long-Term Graft Outcome after Kidney Transplantation KT

M. Fernández-Ruiz

1 , P. Arrazola 1 , F. López-Medrano 1 , J. M. Morales 1 , A. Andrés 1 , J. Gavaldà 2 , J. M. Aguado 1 , C. Lumbreras 1 ; 1 Univ. Hosp. 12 de Octubre, Madrid, Spain, 2 Univ. Hosp. Vall d´Hebron, Barcelona, Spain. T-360 Risk Factors and Prognosis of BK Virus-Associated Hemor- rhagic Cystitis Following Allogeneic Hematopoietic Stem Cell Transplantation

L. Gilis, N. Tedone, G. Billaud, M. Michallet, F. Ader; Hospices Civils de Lyon, Lyon, France.

T-361 BK Polyomavirus BKV IgG is a Predictor of High Level BKV Viruria after Allogeneic Hematopoietic Stem Cell Transplanta- tion HSCT

Y. J. Lee

1 , D. Chung 1 , C. Figueroa 1 , I. Amigues 1 , T. Son 1 , J. Hester 2 , A. Jakubowski 1 , G. Papanicolaou 1 ; 1 Mem. Sloan-Kettering Cancer Ctr., New York, NY, 2 Viracor-IBT Lab., Lee’s Summit, MO. T-362 CMX001 is an Effective Treatment Option for Refractory CMV Infection or Disease in HCT Recipients: A Single Center’s Experience

G. Papanicolaou

1 , H. Mommeja-Marin 2 , M. Anderson 2 , S. Godkin 2 , G. Chittick 2 , W. Painter 2 ; 1 Mem. Sloan Kettering Cancer Ctr., New York, NY, 2 Chimerix, Inc., Durham, NC. T-363 Molecular Decryption of a Group C Adenovirus Epidemic in Pediatric Recipients of Hematopoietic Stem Cells L. Feghoul 1 , P. Roques 2 , J. Dalle 3 , J. Cherot 1 , M. Ouachée 1 , C. Doit 1 , M. Rodier 1 , A. Baruchel 3 , F. Simon 1 , J. Le Goff 1 ; 1 Univ. Paris Diderot, Hôpital Saint-Louis, APHP, Paris, France, 2 IMETI, CEA, Fontenay-aux-Roses, France, 3 Univ. Paris Diderot, Hôpital Robert Debré, APHP, Paris, France. T-364 Good Outcomes Among Hepatitis C HCV-Infected Heart and Lung Transplant Recipients: A Single-Center Experience M. Nguyen 1 , K. Chopra 1 , E. J. Kwak 1 , F. Silveira 1 , R. Abdel-Massih 2 , Y. Toyoda 2 , N. Shigemura 2 , J. Pilewski 1 , M. Crespo 2 , C. Bermudez 1 , J. Bahma 2 ,

C. Clancy

2 ; 1 Univ. of Pittsburgh, Pittsburgh, PA, 2 Univ. of Pittsburgh and VA Pittsburgh, Pittsburgh, PA. T-365 Looking into the Crystal Ball: Can We Foresee CMV?

A. J. Jamal

1 , S. Husain 1,2 , Y. Li 1 , O. Famure 1 , J. S. Kim 1,2 ; 1 Univ. Hlth. Network, Toronto, Canada, 2 Univ. of Toronto, Toronto, Canada. T-366 Safety and Efficacy of a Strategy for Discontinuing Preemptive Ganciclovir Therapy after One Negative Antigenemia Test Result in Kidney Transplantation S. Park, Y. Lee, H. Hong, H. Park, S. Moon, H. Sung, Y. Kim, D. Han, S. Park, J. Park, S. Kim, S. Choi, Y. Kim, J. Woo, S. Lee; Asan Med. Ctr., Seoul, Korea, Republic of. T-367 Acyclovir Resistant Herpes Simplex Virus HSV among Hema- topoietic Stem Cell Transplant HSCT Recipients: Case-Case- Control Investigation D. Patel 1 , D. Marchaim 2 , G. Marcus 2 , R. Gayathri 1 , P. R. Lephart 1 , C. Pranatharthi 1 ; 1 Wayne State Univ., Detroit, MI, 2 Assaf Harofeh Med. Ctr., Zerifin, Israel. 59 SUNDAY SCIENTIFIC SESSIONS Final Program T-368 Impact of Cytomegalovirus CMV Infection in Rapid Progression to Fibrosis and 5-Year Mortality in Liver Transplant Recipients LTR Infected with Hepatitis C Virus HCV O. Len, M. Puig, L. Castells, N. Fernández-Sabé, A. García-Reyne, M. Montejo, R. Lara, G. Bou, J. Gavaldà, A. Pahissa; REIPI Spanish Network for Res. in Infectious Diseases, Barcelona, Spain. T-369 Use of Electronic Estimation of Renal Function eGFR to Guide Valganciclovir VGCV Dosing in Solid-Organ Transplant Recipients SOT-R Commonly Results in Sub-Therapeutic Ganciclovir GCV Levels

J. Trevillyan

1 , P. Angus 1,2 , E. Shelton 1 , J. Whitlam 1 , F. Ierino 1,2 , J. Pavlovic 1 , D. Gregory 1 , K. Urbancic 1 , J. Torresi 1,2 , A. Testro 1 , L. Grayson 1,2 ; 1 Austin Health, Melbourne., Australia, 2 Melbourne Univ., Melbourne, Australia. Late-breaker presentations are listed behind the Late-breaker tab of the Final Program. ------------------------------------------------------------------------ 030 V Poster Session Non HIV Virology Sunday, 11:30 a.m.–1:30 p.m. . . . . . . . . . . . . . . . . . . . . Halls A-C Presentations: V-370 Fluorescent Primuline Derivatives Inhibit Hepatitis C Virus NS3- Catalyzed RNA unwinding, Peptide Hydrolysis and Viral Replicase Formation J. Ndjomou 1 , R. Kolli 1 , S. Mukherjee 1 , K. Li 2 , F. J. Schoenen 2 , D. N. Frick 1 ; 1 Univ. of Wisconsine, Milwaukee, WI, 2 Univ. of Kansas Specialized Chemistry Ctr., Lawrence, KS. V-371 Long-Term Follow-Up of Inner City Populations Treated for HCV Infection

H. Tossonian